Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natesto for male hypogonadism
NCT03203681Phase 4Completed
- Sponsor
- University of Miami
- Start
- Oct 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natesto in Hypogonadism, sponsored by University of Miami. Primary endpoints: Change in Testosterone Levels From Baseline at 27 weeks, Change in Estradiol Levels From Baseline at 27 weeks and 4 more. Started Oct 2017; status: completed.
02
Drugs
natesto
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT03203681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203681.